{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T04:24:48Z","timestamp":1787286288356,"version":"build-2736575974"},"reference-count":28,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>\n                      <jats:italic>Introduction<\/jats:italic>\n                    <\/jats:bold>\n                    . Circulating autoantibodies against phospholipase A2 receptor (anti-PLA2R) are recognized as key elements in the pathogenesis of idiopathic membranous nephropathy. In current clinical practice, they are increasingly gaining attention as novel tools for diagnosis and disease monitoring. We investigated the diagnostic and prognostic utility of anti-PLA2R antibody measurements in Greek patients with biopsy-proven membranous nephropathy.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>\n                      <jats:italic>Methods<\/jats:italic>\n                    <\/jats:bold>\n                    . Anti-PLA2R levels were measured in serum samples from 33 patients at diagnosis using ELISA and were associated with treatment outcome. Moreover, serial anti-PLA2R measurements were performed in 15 patients under different clinical conditions and level alterations were correlated with disease activity.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>\n                      <jats:italic>Results<\/jats:italic>\n                    <\/jats:bold>\n                    . Positive anti-PLA2R antibodies at diagnosis were found in 16 of 33 patients (48.5%). Anti-PLA2R levels were independently associated with the achievement of complete remission of nephrotic syndrome after immunosuppressive treatment compared to partial remission (p = 0.02, R\n                    <jats:sup>2<\/jats:sup>\n                    = 0.265, 95%CI -0.019 to -0.0003). Higher detectable antibody levels at diagnosis were correlated with higher proteinuria levels (r = 0.813, p = 0.0001, 95%CI 0.532 to 0.933) and lower eGFR at the end of follow-up (r = -0.634, p = 0.0083, 95%CI -0.86 to -0.202). Serial antibody measurements during follow-up showed that anti-PLA2R titers were significantly reduced at the end of treatment after complete remission was achieved, remained low under sustained clinical remission, and increased during relapse.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>\n                      <jats:italic>Conclusions<\/jats:italic>\n                    <\/jats:bold>\n                    . Our findings confirm the usefulness of anti-PLA2R measurements in the diagnosis of idiopathic membranous nephropathy. Low levels of anti-PLA2R antibodies at diagnosis are predictive of complete remission of nephrotic syndrome following immunosuppressive treatment. Serial anti-PLA2R measurements correlate well with clinical status throughout the follow-up period and could be used routinely for monitoring of disease activity and treatment planning.\n                  <\/jats:p>","DOI":"10.2478\/rjim-2018-0044","type":"journal-article","created":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T04:03:25Z","timestamp":1547179405000},"page":"141-150","source":"Crossref","is-referenced-by-count":8,"title":["Circulating anti-phospholipase A2 receptor antibodies as a diagnostic and prognostic marker in Greek patients with idiopathic membranous nephropathy \u2013 a retrospective cohort study"],"prefix":"10.2478","volume":"57","author":[{"given":"Simella","family":"Provatopoulou","sequence":"first","affiliation":[{"name":"Department of Nephrology and Renal Transplantation , University Hospital of Patras , Patras , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Kalavrizioti","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Renal Transplantation , University Hospital of Patras , Patras , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Stangou","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hippokration General Hospital , Thessaloniki University School of Medicine , Thessaloniki , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Nikoleta","family":"Kouri","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hippokration General Hospital , Thessaloniki University School of Medicine , Thessaloniki , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pantellitsa","family":"Kalliakmani","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Renal Transplantation , University Hospital of Patras , Patras , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marios","family":"Papasotiriou","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Renal Transplantation , University Hospital of Patras , Patras , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Papachristou","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Renal Transplantation , University Hospital of Patras , Patras , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios S.","family":"Goumenos","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Renal Transplantation , University Hospital of Patras , Patras , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Papagianni","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hippokration General Hospital , Thessaloniki University School of Medicine , Thessaloniki , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2019,6,20]]},"reference":[{"key":"2026082103592601404_j_rjim-2018-0044_ref_001_w2aab3b7c10b1b6b1ab1ab1Aa","doi-asserted-by":"crossref","unstructured":"1. OBRISCA B., ISMAIL G., JURUBITA R., BASTON C., ANDRONESI A., MIRCESCU G. Antiphospholipase A2 Receptor Autoantibodies: A Step Forward in the Management of Primary Membranous Nephropathy. Biomed Res Int. 2015;2015:249740.10.1155\/2015\/249740463037226576418","DOI":"10.1155\/2015\/249740"},{"key":"2026082103592601404_j_rjim-2018-0044_ref_002_w2aab3b7c10b1b6b1ab1ab2Aa","doi-asserted-by":"crossref","unstructured":"2. BECK L.H. JR., BONEGIO R.G., LAMBEAU G., BECK D.M., POWELL D.W., CUMMINS T.D., et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11\u201321.10.1056\/NEJMoa0810457276208319571279","DOI":"10.1056\/NEJMoa0810457"},{"key":"2026082103592601404_j_rjim-2018-0044_ref_003_w2aab3b7c10b1b6b1ab1ab3Aa","doi-asserted-by":"crossref","unstructured":"3. SVOBODOVA B., HONSOVA E., RONCO P., TESAR V., DEBIEC H. Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy. Nephrol Dial Transplant. 2013;28(7):1839\u201344.10.1093\/ndt\/gfs43923223223","DOI":"10.1093\/ndt\/gfs439"},{"key":"2026082103592601404_j_rjim-2018-0044_ref_004_w2aab3b7c10b1b6b1ab1ab4Aa","doi-asserted-by":"crossref","unstructured":"4. HOFSTRA J.M., BECK L.H. JR., BECK D.M., WETZELS J.F., SALANT D.J., Anti-phospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2011;6(6):1286\u201391.10.2215\/CJN.07210810310992321474589","DOI":"10.2215\/CJN.07210810"},{"key":"2026082103592601404_j_rjim-2018-0044_ref_005_w2aab3b7c10b1b6b1ab1ab5Aa","unstructured":"5. SEGARRA-MEDRANO A., JATEM-ESCALANTE E., CARNICER-C\u00c1CERES C., AGRAZ-PAMPLONA I., SALCEDO M.T., VALTIERRA N., et al. Evolution of antibody titre against the M-type phospholipase A2 receptor and clinical response in idiopathic membranous nephropathy patients treated with tacrolimus. Nefrologia. 2014;34(4):491-7."},{"key":"2026082103592601404_j_rjim-2018-0044_ref_006_w2aab3b7c10b1b6b1ab1ab6Aa","doi-asserted-by":"crossref","unstructured":"6. KANIGICHERLA D., GUMMADOVA J., MCKENZIE E.A., ROBERTS S.A., HARRIS S., NIKAM M., et al. Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney Int. 2013;83(5):940\u20138.10.1038\/ki.2012.48623364522","DOI":"10.1038\/ki.2012.486"},{"key":"2026082103592601404_j_rjim-2018-0044_ref_007_w2aab3b7c10b1b6b1ab1ab7Aa","doi-asserted-by":"crossref","unstructured":"7. BECK L.H. JR, FERVENZA F.C., BECK D.M., BONEGIO R.G., MALIK F.A., ERICKSON S.B., et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol. 2011;22(8):1543-50.10.1681\/ASN.2010111125314870921784898","DOI":"10.1681\/ASN.2010111125"},{"key":"2026082103592601404_j_rjim-2018-0044_ref_008_w2aab3b7c10b1b6b1ab1ab8Aa","doi-asserted-by":"crossref","unstructured":"8. RAMACHANDRAN R., KUMAR V., SINGH N., KATARUKA M., RATHI M.,KOHLI H.S., et al. Utility of determining autoantibodies to M-type phospholipase A2 receptor in diagnosing primary membranous nephropathy: An ideal setting. Indian J Nephrol. 2017;27(5):413-415.10.4103\/ijn.IJN_165_16559042528904444","DOI":"10.4103\/ijn.IJN_165_16"},{"key":"2026082103592601404_j_rjim-2018-0044_ref_009_w2aab3b7c10b1b6b1ab1ab9Aa","doi-asserted-by":"crossref","unstructured":"9. TOMAS N.M., BECK L.H. JR, MEYER-SCHWESINGER C., SEITZ-POLSKI B., MA H., ZAHNER G., et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med. 2014;371(24):2277\u201387.10.1056\/NEJMoa1409354427875925394321","DOI":"10.1056\/NEJMoa1409354"},{"key":"2026082103592601404_j_rjim-2018-0044_ref_010_w2aab3b7c10b1b6b1ab1ac10Aa","unstructured":"10. KDIGO Clinical practice guideline for glomerulonephritis. Kidney Int 2012;2 (Suppl 2):186-197."},{"key":"2026082103592601404_j_rjim-2018-0044_ref_011_w2aab3b7c10b1b6b1ab1ac11Aa","doi-asserted-by":"crossref","unstructured":"11. DU Y., LI J., HE F., LV Y., LIU W., WU P., et al. The diagnosis accuracy of PLA2R-AB in the diagnosis of idiopathic membranous nephropathy: A meta-analysis. PLoS One. 2014;9(8):e104936.10.1371\/journal.pone.0104936413815425136841","DOI":"10.1371\/journal.pone.0104936"},{"key":"2026082103592601404_j_rjim-2018-0044_ref_012_w2aab3b7c10b1b6b1ab1ac12Aa","doi-asserted-by":"crossref","unstructured":"12. HOFSTRA J.M., DEBIEC H., SHORT C.D., PELL\u00c9 T., KLETA R., MATHIESON P.W., et al. Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J Am Soc Nephrol. 2012;23(10):1735\u201343.10.1681\/ASN.2012030242345846522956816","DOI":"10.1681\/ASN.2012030242"},{"key":"2026082103592601404_j_rjim-2018-0044_ref_013_w2aab3b7c10b1b6b1ab1ac13Aa","doi-asserted-by":"crossref","unstructured":"13. BRENCHLEY P.E. Anti-phospholipase A2 receptor antibody and immunosuppression in membranous nephropathy: more evidence for pathogenicity of anti-phospholipase a2 receptor autoantibodies. J Am Soc Nephrol. 2015;26(10):2308-11.10.1681\/ASN.2015020181458770825804283","DOI":"10.1681\/ASN.2015020181"},{"key":"2026082103592601404_j_rjim-2018-0044_ref_014_w2aab3b7c10b1b6b1ab1ac14Aa","doi-asserted-by":"crossref","unstructured":"14. VAN DE LOGT A.E., HOFSTRA J.M., WETZELS J.F. Serum anti-PLA2R antibodies can be initially absent in idiopathic membranous nephropathy: seroconversion after prolonged follow-up. Kidney Int. 2015;87(6):1263-4.10.1038\/ki.2015.3426024039","DOI":"10.1038\/ki.2015.34"},{"key":"2026082103592601404_j_rjim-2018-0044_ref_015_w2aab3b7c10b1b6b1ab1ac15Aa","doi-asserted-by":"crossref","unstructured":"15. GOPALAKRISHNAN N., ABEESH P., DINESHKUMAR T., MURUGANANTH S., SAKTHIRAJAN R., RAMAN G.S., et al. Prevalence of serum anti M-type phospholipase A2 receptor antibody in primary membranous nephropathy: A single center experience. Indian J Nephrol. 2016;26(4):257-61.10.4103\/0971-4065.160334496468527512297","DOI":"10.4103\/0971-4065.160334"},{"key":"2026082103592601404_j_rjim-2018-0044_ref_016_w2aab3b7c10b1b6b1ab1ac16Aa","doi-asserted-by":"crossref","unstructured":"16. LI X., WEI D., ZHOU Z., WANG B., XU Y., PAN J., et al. Anti-PLA2R Antibodies in Chinese patients with membranous nephropathy. Med Sci Monit. 2016;22:1630-6.10.12659\/MSM.896090","DOI":"10.12659\/MSM.896090"},{"key":"2026082103592601404_j_rjim-2018-0044_ref_017_w2aab3b7c10b1b6b1ab1ac17Aa","doi-asserted-by":"crossref","unstructured":"17. OH Y.J., YANG S.H., KIM D.K., KANG S.W., KIM Y.S. Autoantibodies against phospholipase A2 receptor in Korean patients with membranous nephropathy. PLoS One. 2013;8(4):e62151.10.1371\/journal.pone.0062151363739023637987","DOI":"10.1371\/journal.pone.0062151"},{"key":"2026082103592601404_j_rjim-2018-0044_ref_018_w2aab3b7c10b1b6b1ab1ac18Aa","doi-asserted-by":"crossref","unstructured":"18. HILL P.A., MCRAE J.L., DWYER K.M. PLA2R and membranous nephropathy: A 3-year prospective Australian study. Nephrology (Carlton). 2016;21(5):397-403.10.1111\/nep.1262426369693","DOI":"10.1111\/nep.12624"},{"key":"2026082103592601404_j_rjim-2018-0044_ref_019_w2aab3b7c10b1b6b1ab1ac19Aa","unstructured":"19. ARDALAN M., GHAFARI A., HAMZAVI F., NASRI H., BARADARAN B., MAJIDI J., et al. Anti-phospholipase A2 receptor antibody in idiopathic membranous nephropathy: A report from Iranian population. J Nephropath. 2013;2(4):241-8."},{"key":"2026082103592601404_j_rjim-2018-0044_ref_020_w2aab3b7c10b1b6b1ab1ac20Aa","doi-asserted-by":"crossref","unstructured":"20. QIN W., BECK L.H. JR, ZENG C., CHEN Z., LI S., ZUO K., et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol. 2011;22(6):1137\u201343.10.1681\/ASN.2010090967310373321566055","DOI":"10.1681\/ASN.2010090967"},{"key":"2026082103592601404_j_rjim-2018-0044_ref_021_w2aab3b7c10b1b6b1ab1ac21Aa","doi-asserted-by":"crossref","unstructured":"21. RUGGENENTI P., DEBIEC H., RUGGIERO B., CHIANCA A., PELL\u00c9 T., GASPARI F., et al. Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy. J Am Soc Nephrol. 2015;26(10):2545-58.10.1681\/ASN.2014070640458768825804280","DOI":"10.1681\/ASN.2014070640"},{"key":"2026082103592601404_j_rjim-2018-0044_ref_022_w2aab3b7c10b1b6b1ab1ac22Aa","doi-asserted-by":"crossref","unstructured":"22. TIMMERMANS S.A., ABDUL HAMID M.A., COHEN TERVAERT J.W., DAMOISEAUX J.G., VAN PAASSEN P.; LIMBURG RENAL REGISTRY. Anti-PLA2R antibodies as a prognostic factor in PLA2R-related membranous nephropathy. Am J Nephrol. 2015;42(1):70-7.10.1159\/00043723626344651","DOI":"10.1159\/000437236"},{"key":"2026082103592601404_j_rjim-2018-0044_ref_023_w2aab3b7c10b1b6b1ab1ac23Aa","doi-asserted-by":"crossref","unstructured":"23. POURCINE F., DAHAN K., MIHOUT F., CACHANADO M., BROCHERIOU I., DEBIEC H., et al. Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: A single-centre study over 14 years. PLoS One. 2017;12(3):e0173201.10.1371\/journal.pone.0173201533629428257452","DOI":"10.1371\/journal.pone.0173201"},{"key":"2026082103592601404_j_rjim-2018-0044_ref_024_w2aab3b7c10b1b6b1ab1ac24Aa","doi-asserted-by":"crossref","unstructured":"24. HOXHA E., THIELE I., ZAHNER G., PANZER U., HARENDZA S., STAHL R.A. Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. J Am Soc Nephrol. 2014;25(6):1357-66.10.1681\/ASN.2013040430403336524610926","DOI":"10.1681\/ASN.2013040430"},{"key":"2026082103592601404_j_rjim-2018-0044_ref_025_w2aab3b7c10b1b6b1ab1ac25Aa","doi-asserted-by":"crossref","unstructured":"25. RADICE A., TREZZI B., MAGGIORE U., PREGNOLATO F., STELLATO T., NAPODANO P., et al. Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN). Autoimmun Rev. 2016;15(2):146-54.10.1016\/j.autrev.2015.10.00426527329","DOI":"10.1016\/j.autrev.2015.10.004"},{"key":"2026082103592601404_j_rjim-2018-0044_ref_026_w2aab3b7c10b1b6b1ab1ac26Aa","doi-asserted-by":"crossref","unstructured":"26. BECH A.P., HOFSTRA J.M., BRENCHLEY P.E., WETZELS J.F. Association of anti-PLA2R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2014;9(8):1386\u201392.10.2215\/CJN.10471013412340225035272","DOI":"10.2215\/CJN.10471013"},{"key":"2026082103592601404_j_rjim-2018-0044_ref_027_w2aab3b7c10b1b6b1ab1ac27Aa","doi-asserted-by":"crossref","unstructured":"27. LIU Y., LI X., MA C., WANG P., LIU J., SU H., et al. Serum anti-PLA2R antibody as a diagnostic biomarker of idiopathic membranous nephropathy: The optimal cut-off value for Chinese patients. Clin Chim Acta. 2018;476:9-14.10.1016\/j.cca.2017.11.00629126817","DOI":"10.1016\/j.cca.2017.11.006"},{"key":"2026082103592601404_j_rjim-2018-0044_ref_028_w2aab3b7c10b1b6b1ab1ac28Aa","doi-asserted-by":"crossref","unstructured":"28. TAMPOIA M., MIGLIUCCI F., VILLANI C., ABBRACCIAVENTO L., ROSSINI M., FUMARULO R., et al. Definition of a new cut-off for the anti-phospholipase A2 receptor (PLA2R) autoantibody immunoassay in patients affected by idiopathic membranous nephropathy. J Nephrol. 2018;31(6):899-905.10.1007\/s40620-018-0533-z30187382","DOI":"10.1007\/s40620-018-0533-z"}],"container-title":["Romanian Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/content.sciendo.com\/view\/journals\/rjim\/57\/2\/article-p141.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/rjim-2018-0044","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T03:59:51Z","timestamp":1787284791000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/rjim-2018-0044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,1]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,6,20]]},"published-print":{"date-parts":[[2019,6,1]]}},"alternative-id":["10.2478\/rjim-2018-0044"],"URL":"https:\/\/doi.org\/10.2478\/rjim-2018-0044","relation":{},"ISSN":["2501-062X"],"issn-type":[{"value":"2501-062X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,1]]}}}